医学
西妥昔单抗
贝伐单抗
结直肠癌
癌症
疾病
化疗
乳腺癌
临床实习
辅助化疗
重症监护医学
阶段(地层学)
肿瘤科
内科学
家庭医学
古生物学
生物
作者
Roberto Labianca,Giordano Beretta,B. Kildani,Laura Milesi,F. Merlin,S. Mosconi,Maria Adelaide Pessi,Tiziana Prochilo,Antonello Quadri,Gemma Gatta,Filippo de Braud,J. Wils
标识
DOI:10.1016/j.critrevonc.2010.01.010
摘要
Colon cancer is one of the leading tumours in the world and it is considered among the big killers, together with lung, prostate and breast cancer. In the recent years very important advances occurred in the field of treatment of this frequent disease: adjuvant chemotherapy was demonstrated to be effective, chiefly in stage III patients, and surgery was optimized in order to achieve the best results with a low morbidity. Several new target-oriented drugs are under evaluation and some of them (cetuximab and bevacizumab) have already exhibited a good activity/efficacy, mainly in combination with chemotherapy. The development of updated recommendations for the best management of these patients is crucial in order to obtain the best results, not only in clinical research but also in every-day practice. This report summarizes the most important achievements in this field and provides the readers useful suggestions for their professional practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI